Journal
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Volume 145, Issue -, Pages 84-87Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.yjmcc.2020.06.007
Keywords
Apelin; COVID-19; Renin-angiotensin system
Categories
Ask authors/readers for more resources
We believe that, in parallel to the attempts for direct blockade of the SARS-CoV-2 penetration into host cell and repurposing drugs, finding new therapeutic strategies for patients with lung injury or cardiovascular complications/coagulopathies associated with COVID-19 should be paid particular attention. Apelin or its receptor agonists are of great potential treatment for COVID-19 through suppressing angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) production, as well as, down-regulating angiotensin receptor 1 (AT1R) and ACE2 up-regulation. These drugs have potential to improve acute lung injury and cardiovascular/coagulopathy complications in COVID-19 which are associated with elevated Ang-II/Ang(1-7) ratio.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available